A5020620783- SARS-CoV-2 and COVID-19 Research
- Vaccine Coverage and Hesitancy
- COVID-19 Clinical Research Studies
- Monoclonal and Polyclonal Antibodies Research
- Heparin-Induced Thrombocytopenia and Thrombosis
- Viral gastroenteritis research and epidemiology
- Pain Management and Treatment
- Animal Virus Infections Studies
- Hepatitis B Virus Studies
- Viral Infections and Outbreaks Research
- Botulinum Toxin and Related Neurological Disorders
- Immunotherapy and Immune Responses
- Bacterial Infections and Vaccines
- vaccines and immunoinformatics approaches
- Complement system in diseases
- Pain Mechanisms and Treatments
- COVID-19 Impact on Reproduction
- Hepatitis Viruses Studies and Epidemiology
- Peripheral Neuropathies and Disorders
- Influenza Virus Research Studies
- Magnetic and Electromagnetic Effects
- COVID-19 epidemiological studies
- Photosynthetic Processes and Mechanisms
- interferon and immune responses
- SARS-CoV-2 detection and testing
Novavax (United States)
2022-2025
Albany Medical Center Hospital
2019-2022
Siena College
2016
Monovalent SARS-CoV-2 Prototype (Wuhan-Hu-1) and bivalent (Prototype + BA.4/5) COVID-19 vaccines have demonstrated a waning of vaccine-mediated immunity highlighted by lower neutralizing antibody responses against Omicron XBB sub-variants. The reduction humoral due to the rapid evolution has signaled need for an update vaccine composition. A strain change all authorized/approved monovalent composition with subvariant XBB.1.5 been supported WHO, EMA, FDA. Here, we demonstrate that...
As SARS-CoV-2 variants continue to emerge, vaccination remains a critical tool reduce the COVID-19 burden. Vaccine reactogenicity and impact on work productivity/daily activities are recognized as contributing factors vaccine hesitancy. To encourage continued vaccination, more complete understanding of differences in impairment due vaccine-related side effects across currently available vaccines is necessary. The 2019nCoV-406 study (n = 1367) was prospective observational associated...
Abstract Background IgG4, the least abundant human IgG subtype, increases after repetitive exposure to some antigens, and may induce immune tolerance. Studies have found that repeat mRNA SARS-CoV-2 vaccination leads large proportional in spike (S)-specific IgG4. By contrast, increased IgG4 has not been observed following with recombinant S (rS) protein (NVX-CoV2373, Novavax). Whether vaccine-induced anti-S might impair immunity remains unknown.Figure:Serum anti-Spike IgG1 (A), IgG3 (B), (C)...
Abstract Background Post-marketing assessments of vaccine effectiveness (VE) are critical to informing health policy, understanding real-world performance, and ensuring confidence in vaccination efforts, though imperfect comparator groups can limit the accuracy VE assessments. The self-controlled risk interval (SCRI) design, a case-only analytic method historically used safety studies, controls for time-invariant confounding using within-person comparisons has recently been assess VE. This...
Abstract Background There is a public health need for annual immunizations against both SARS-CoV-2 and influenza viruses. We developed standalone saponin-adjuvanted (Matrix-M™) recombinant quadrivalent hemagglutinin (HA) nanoparticle vaccine (qNIV), COVID combination (CIC) vaccine, comprising Spike (rS) (NVX-CoV2373), qNIV, Matrix-M adjuvant.Table 1.Study design Methods Participants in Australia New Zealand (1571 treated, including 864 the CIC group) aged 50–80 years were randomized equally...
Proportional increases in anti-Spike (S) IgG4 associated with decreased Fc effector functions have been reported following repeated mRNA, but not recombinant protein-based (rS) (NVX-CoV2373, Novavax), SARS-CoV-2 vaccination. We demonstrate the first evidence of a negative correlation between anti-S and neutralizing antibody (nAb) as well antibody-dependent functions. Priming two NVX-CoV2373 vaccines followed by third dose was higher IgG1 IgG3, lower IgG4, nAb titers versus mRNA. Immune...
Abstract Repeated mRNA SARS-CoV-2 vaccination has been associated with increases in the proportion of IgG4 spike-specific antibody responses and concurrent reductions Fcγ-mediated effector functions that may limit control viral infection. Here, we assessed anti-Spike total IgG, IgG1, IgG2, IgG3 IgG4, surrogate markers for antibody-dependent cellular phagocytosis (ADCP, FcγRIIa binding), cytotoxicity (ADCC, FcγRIIIa complement deposition (ADCD, C1q binding) repeated NVX-CoV2373 (Novavax Inc.,...
This phase 3 observer-blind, randomized, controlled study was conducted in adults ≥18 years of age to assess the safety and immunogenicity NVX-CoV2373 as a heterologous booster compared BBIBP-CorV when utilized homologous booster. Approximately 1000 participants were randomly assigned 1:1 ratio receive single dose or after prior vaccination with 2 doses BBIBP-CorV. Solicited adverse events (AEs) collected for 7 days vaccination. Unsolicited AEs 28 following serious special interest (AESI)...
Given that the Ebola virus (EBOV) infects a wide array of organs and cells yet displays relative lack neurotropism, we asked whether chimeric vesicular stomatitis (VSV) expressing EBOV glycoprotein (GP) might selectively target brain tumors. The mucin-like domain (MLD) GP may enhance immune system evasion. Here, compared VSVs in which replaces VSV glycoprotein, thereby reducing neurotoxicity associated with wild-type VSV. A full-length (VSV-EBOV) containing MLD was substantially more...
Abstract This phase 3 observer-blind, randomized, controlled study was conducted in adults ≥18 years of age to assess the safety and immunogenicity NVX-CoV2373 as a heterologous booster compared BBIBP-CorV when utilized homologous booster. Approximately 1,000 participants were randomly assigned 1:1 ratio receive single dose or after prior vaccination with 2 doses BBIBP-CorV. Solicited adverse events (AEs) collected for 7 days vaccination. Unsolicited AEs 28 following serious special interest...
Despite spinal cord stimulation's (SCS) proven efficacy, failure rates are high with no clear understanding of which patients benefit long term. Currently, patient selection for SCS is based on the subjective experience implanting physician.To develop machine learning (ML)-based predictive models long-term response.A combined unsupervised (clustering) and supervised (classification) ML technique was applied a prospectively collected cohort 151 patients, included 31 features. Clusters...
Participants in studies investigating COVID-19 vaccines commonly report reactogenicity events, and concerns about side effects may lead to a reluctance receive updated vaccinations. A real-world, post hoc analysis, observational 2019nCoV-406 study was conducted examine within the first 2 days after vaccination with either protein-based vaccine (NVX-CoV2373) or an mRNA (BNT162b2 mRNA-1273) individuals who previously completed primary series. Propensity score adjustments were address potential...
PREVENT-19, the pivotal phase 3 trial of Novavax adjuvanted, recombinant spike protein COVID-19 vaccine (NVX-CoV2373), demonstrated that was well tolerated and efficacious (vaccine efficacy, VE = 90%) for prevention symptomatic COVID-19. In trial, participants were randomly assigned in a 2:1 ratio to receive 2 doses NVX-CoV2373 or placebo 21 days apart. Throughout study, predominant SARS-CoV-2 variant alpha, but additional variants circulation (i.e., beta, gamma, epsilon, iota). among...
Introduction Approximately half of the 13.4 billion COVID-19 vaccine doses administered globally were inactivated or viral vector platforms. The harmonization and optimization regimens has become a key focus policy makers healthcare providers presents an opportunity to reassess continued use pandemic-era vaccines.Areas covered Immunological evidence from studies various homologous heterologous been rapidly published, however interpretation these data are complicated by many types highly...
Abstract Monovalent SARS-CoV-2 Prototype (Wuhan-Hu-1) and bivalent (Prototype + BA.4/5) COVID-19 vaccines have demonstrated a waning of vaccine-mediated immunity highlighted by lower neutralizing antibody responses against Omicron XBB sub-variants. The reduction humoral due to the rapid evolution has signaled need for an update vaccine composition. A strain change all authorized/approved monovalent composition with subvariant XBB.1.5 been supported WHO, EMA, FDA. Here, we demonstrate that...
Over 50% of the 34 million people who suffer from diabetes mellitus (DM) are affected by diabetic neuropathy. Painful neuropathy (PDN) impacts 40-50% that group (8.5 patients) and is associated with a significant source disability economic burden. Though new neuromodulation options have been successful in recent clinical trials (NCT03228420), still there many barriers restrict patients access to these therapies. We seek examine our tertiary care center (Albany Medical Center, NY, USA)...
Abstract A prospective, observational study investigated the burden and impact of vaccine reactogenicity in adults from United States Canada who received an approved/authorized mRNA COVID-19 or Novavax COVID as a booster dose. As part real-world study, reactogenic events captured via patient symptom diaries were compared. Results demonstrated that overall percentage recipients experiencing any event (77.6%) was lower than doses (95.9%).
Virus-like vesicles (VLV) are infectious, self-propagating alphavirus-vesiculovirus hybrid vaccine vectors that can be engineered to express foreign antigens elicit a protective immune response. VLV highly immunogenic and nonpathogenic in vivo, we hypothesize the unique replication structural characteristics of efficiently induce an innate antiviral response enhances immunogenicity limits spread vector. We found is inhibited by interferon (IFN)-α, IFN-γ, IFN-λ, but not tumor necrosis...